Market Research Logo

US Market Report for Implantable Ports - MedCore

The U.S. market for implantable ports comprises conventional implantable ports, power-injectableimplantable ports and valved implantable ports. Conventional implantable ports are defined asimplantable ports that do not feature power-injection. Valved implantable ports are designed toprevent the backflow of blood and reduce catheter-related complications.Power-injectable ports became available in the U.S. in 2007 and allowed the total implantable portmarket to be further segmented into conventional and power-injectable models. Valved ports are alsopresent in the U.S. market but there is only one company manufacturing them, and the devices have alimited penetration in the total implantable port market.


EXECUTIVE SUMMARY
1.1 U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
1.2 COMPETITIVE LANDSCAPE
1.3 MARKET TRENDS
1.4 KEY MARKET DEVELOPMENTS
1.5 MARKETS INCLUDED
1.6 PROCEDURES INCLUDED
1.7 PROCEDURE CODES INVESTIGATED
1.8 KEY REPORT UPDATES
1.9 VERSION HISTORY
RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
3.1 BASIC ANATOMY
3.1.1 Human Vascular System
3.2 VASCULAR PATHOLOGY AND DISORDERS
3.2.1 Cancer
3.2.2 End-Stage Renal Disease
3.2.3 Diabetes
3.3 PATIENT DEMOGRAPHICS
3.3.1 Cancer
3.3.1.1 Digestive Cancer
3.3.1.2 Genital Cancer
3.3.1.3 Breast Cancer
3.3.1.4 Respiratory Cancer
3.3.1.5 Urinary Cancer
3.3.1.6 Skin Cancer
3.3.1.7 Lymphoma
3.3.1.8 Endocrine System Cancer
3.3.1.9 Leukemia
3.3.1.10 Oral Cavity/Larynx
3.3.1.11 Myeloma
3.3.1.12 Brain/Other Nervous System
3.3.1.13 Soft Tissue (including heart)
3.3.1.14 Bones and Joints
3.3.1.15 Eye and Orbit
3.3.2 End-Stage Renal Disease
3.3.2.1 End-Stage Renal Disease Incidence
3.3.2.1.1 End-Stage Renal Disease Incident Cases by Modality
3.3.2.1.2 End-Stage Renal Disease Incident Cases by Age Group
3.3.2.1.3 End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
3.3.2.2 Vascular Access Use at Hemodialysis Initiation
3.3.2.2.1 Vascular Access Use During First Year of Hemodialysis
3.3.2.2.1.1 Vascular Access Use During First Year of Hemodialysis by Age Group
3.3.2.3 Stage Renal Disease Prevalence
3.3.2.3.1 End-Stage Renal Disease Prevalent Cases by Modality
3.3.2.3.1.1 Prevalent Hemodialysis Patients by Vascular Access Type
3.3.2.3.2 End-Stage Renal Disease Prevalent Cases by Age Group
3.3.2.3.3 End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
3.3.3 Diabetes
3.3.3.1 Diagnosed Diabetes Incidence Amongst Adults
3.3.3.1.1 Diagnosed Diabetes Incidence Amongst Adults by State
3.3.3.2 Diagnosed Diabetes Prevalence Amongst Adults
3.3.3.2.1 Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
3.3.3.2.2 Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
3.3.3.2.3 Diagnosed Diabetes Prevalence Amongst Adults by State and Gender
PRODUCT ASSESSMENT
4.1 PRODUCT PORTFOLIOS
4.1.1 Implantable Port Devices
4.1.1.1 Introduction
4.1.1.1.1 Implantable Port Patients
4.1.1.1.2 Port Implantation Procedures
4.1.1.1.3 Port Infusion
4.1.1.1.4 Port Maintenance
4.1.1.2 AngioDynamics
4.1.1.2.1 BioFlo®
4.1.1.2.2 LifePort®
4.1.1.2.3 Smart Port® CT
4.1.1.2.4 TitanPort®
4.1.1.2.5 Triumph-1®
4.1.1.2.6 Vortex®
4.1.1.2.7 Xcela™ Plus
4.1.1.3 B. Braun
4.1.1.3.1 Celsite®
4.1.1.4 Cook Medical
4.1.1.4.1 Vital-Port®
4.1.1.5.1 PowerPort®
4.1.1.5.2 SlimPort®
4.1.1.5.3 X-Port™
4.1.1.5.4 Other Port Offerings
4.1.1.6 Medcomp
4.1.1.6.1 Dignity®
4.1.1.6.2 Pro-Fuse® CT
4.1.1.7 PFM Medical
4.1.1.7.1 T-Port™
4.1.1.7.2 TitaJet™
4.1.1.7.3 Jet Port®
4.1.1.7.4 DualPort
4.1.1.8 Smiths Medical
4.1.1.8.1 P.A.S. PORT®
4.1.1.8.2 PORT-A-CATH®
4.1.1.9 Teleflex Medical
4.1.1.9.1 Polysite®
IMPLANTABLE PORT MARKET
5.1 MARKET OVERVIEW
5.1.1 Implantable Port Market Overview by Device Type
5.1.2 Implantable Port Market Overview by Material
5.2 MARKET ANALYSIS AND FORECAST
5.2.1 Total Implantable Port Market
5.2.2 Implantable Port Market by Device Type
5.2.2.1 Total Conventional Implantable Port Market
5.2.2.1.1 Single-Lumen Conventional Implantable Port Market
5.2.2.1.2 Double-Lumen Conventional Implantable Port Market
5.2.2.2 Total Power-Injectable Implantable Port Market
5.2.2.2.1 Single-Lumen Power-Injectable Implantable Port Market
5.2.2.2.2 Double-Lumen Power-Injectable Implantable Port Market
5.2.2.3 Total Valved Implantable Port Market
Plastic Implantable 5.2.3.1 Port Market
5.2.3.2 Titanium Implantable Port Market
5.3 DRIVERS AND LIMITERS
5.3.1 Market Drivers
5.3.2 Market Limiters
5.4 COMPETITIVE MARKET SHARE ANALYSIS
List of Chart
Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012 – 2022
Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996 – 2015
Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996 – 2015
Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996 – 2015
Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015 83
Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005 – 2015
Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013 – 2014
Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996 – 2015
Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996 – 2015
Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003 – 2015
Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996 – 2015
Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997 – 2015
Chart 5-1: Implantable Port Market by Device Type, U.S., 2012 – 2022
Chart 5-2: Implantable Port Market Breakdown by Device Type, U.S., 2015
Chart 5-3: Implantable Port Market Breakdown by Device Type, U.S., 2022
Chart 5-4: Implantable Port Market by Material, U.S., 2012 – 2022
Chart 5-5: Implantable Port Market Breakdown by Material, U.S., 2015
Chart 5-6: Implantable Port Market Breakdown by Material, U.S., 2022
Chart 5-7: Total Implantable Port Market, U.S., 2012 – 2022
Chart 5-8: Total Conventional Implantable Port Market, U.S., 2012 – 2022
Chart 5-9: Single-Lumen Conventional Implantable Port Market, U.S., 2012 – 2022
Chart 5-10: Double-Lumen Conventional Implantable Port Market, U.S., 2012 – 2022
Chart 5-11: Total Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Chart 5-12: Single-Lumen Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Chart 5-13: Double-Lumen Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Chart 5-14: Total Valved Implantable Port Market, U.S., 2012 – 2022
Chart 5-15: Plastic Implantable Port Market, U.S., 2012 – 2022
Chart 5-16: Titanium Implantable Port Market, U.S., 2012 – 2022
Chart 5-17: Leading Competitors, Implantable Port Market, U.S., 2015
List of Figures
Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
Figure 0-3: Companies Researched in Report, U.S., 2015
Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012 – 2015
Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
Figure 0-10: Procedural Codes, U.S., 2015
Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
Figure 0-13: Version History
Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996 – 2015
Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996 – 2015
Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996 – 2015
Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005 – 2015
Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013 – 2014
Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013 – 2014
Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013 – 2014
Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996 – 2015
Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996 – 2015
Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003 – 2015
Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996 – 2015
Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997 – 2015
Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997 – 2015
Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997 – 2015
Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
Figure 5-1: Implantable Port Market by Device Type, U.S., 2012 – 2022 (US$M)
Figure 5-2: Implantable Port Market by Material, U.S., 2012 – 2022 (US$M)
Figure 5-3: Total Implantable Port Market, U.S., 2012 – 2022
Figure 5-4: Total Conventional Implantable Port Market, U.S., 2012 – 2022
Figure 5-5: Single-Lumen Conventional Implantable Port Market, U.S., 2012 – 2022
Figure 5-6: Double-Lumen Conventional Implantable Port Market, U.S., 2012 – 2022
Figure 5-7: Total Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Figure 5-8: Single-Lumen Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Figure 5-9: Double-Lumen Power-Injectable Implantable Port Market, U.S., 2012 – 2022
Figure 5-10: Total Valved Implantable Port Market, U.S., 2012 – 2022
Figure 5-11: Plastic Implantable Port Market, U.S., 2012 – 2022
Figure 5-12: Titanium Implantable Port Market, U.S., 2012 – 2022
Figure 5-13: Drivers and Limiters, Implantable Port Market, U.S., 2015
Figure 5-14: Leading Competitors, Implantable Port Market, U.S., 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report